Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Arvinas Holding Company ( (ARVN) ) is now available.
On June 13, 2025, Arvinas, Inc. presented data from preclinical studies of ARV-393, a PROTAC BCL6 degrader, at the European Hematology Association Congress in Milan. The studies showed significant single-agent activity of ARV-393 in models of nodal T-follicular helper cell lymphoma and transformed follicular lymphoma, as well as enhanced antitumor activity in combination with small molecule inhibitors in models of aggressive diffuse large B-cell lymphoma. These findings suggest potential broad utility for ARV-393 across non-Hodgkin lymphoma subtypes and support the exploration of combination strategies, including chemotherapy-free approaches.
The most recent analyst rating on (ARVN) stock is a Buy with a $87.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.
Spark’s Take on ARVN Stock
According to Spark, TipRanks’ AI Analyst, ARVN is a Neutral.
Arvinas’ overall stock score reflects strong strategic progress and positive corporate developments, but ongoing financial challenges and a lack of profitability weigh on the overall outlook. The positive sentiment from recent earnings calls and corporate events partially offsets these concerns.
To see Spark’s full report on ARVN stock, click here.
More about Arvinas Holding Company
Arvinas, Inc. is a clinical-stage biotechnology company headquartered in New Haven, Connecticut, specializing in the development of protein degradation therapies through its PROTAC protein degrader platform. The company is focused on creating drugs to treat debilitating and life-threatening diseases, with products targeting conditions such as breast cancer, non-Hodgkin lymphoma, neurodegenerative disorders, and cancers with specific mutations.
Average Trading Volume: 2,718,734
Technical Sentiment Signal: Sell
Current Market Cap: $559.8M
See more insights into ARVN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue